Work

Multicenter, Dose-Escalation Study of the Investigational Drug Tak-733, An Oral Mek inhibitor, in Patients (PTS) with Advanced Solid Tumors: Preliminary Phase 1 Results

Year: 2012

Type: article

Study design: Clinical Trial

Source: Annals of Oncology

DOI: 10.1016/s0923-7534(20)33014-3

Authors: A.A. Adjei, P.M. LoRusso, A. Ribas, J.A. Sosman, G.K. Dy, B. Chmielowski, P. Lipman, X. Zhou, E. Gangolli, V. Bozón

Institutions: Roswell Park Comprehensive Cancer Center, The Barbara Ann Karmanos Cancer Institute, University of California, Los Angeles, UCLA Jonsson Comprehensive Cancer Center, Vanderbilt University Medical Center, Takeda Oncology (United States)

Language: English

Topic: Melanoma and MAPK Pathways

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W2998865411

FWCI: 0.233

Cites:

Cited by: 4

Related to: 10